Deals in Depth: September 2009
Executive Summary
Boston Scientific's lawsuit settlement with Cordis and concurrent IP license topped the alliance list at $716 million. Even without counting the two monster IPOs by Talecris ($550 million) and China's Sinopharm ($1.1 billion), total money raised in biopharma still increased in September by 26%. Device financing decreased by over $100 million to $266 million.